UK’s NICE Backs BMS's Opdivo In Lung Cancer, But Only Via CDF With Price Cut
Executive Summary
UK HTA body NICE has decided to make Bristol-Myers Squibb's PD-1 inhibitor Opdivo available for non-small-cell lung cancer, but only through the UK's revamped Cancer Drugs Fund, and at a discounted price.
You may also be interested in...
Opdivo Use For Urothelial Cancer Blocked By NICE In Draft Guidance
Opdivo has failed to convince the UK's pricing watchdog, NICE, of its value and benefit for patients with advanced urothelial cancer; in its draft decision the reimbursement body has also rejected the drug for use on the Cancer Drugs Fund.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.